Shanghai Haohai Biological Technology688366.SHValuation Analysis

As of Oct 19, 2026, Shanghai Haohai Biological Technology (688366.SH) trades at a P/E of 44.70x, P/B of 1.29x, P/S of 2.89x, and a dividend yield of 3.65%.
Longitudinal percentile comparison: P/E sits at the 44th percentile over the trailing 10Y window (vs. 86th percentile over 3Y); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 4th percentile over 3Y); P/S sits at the 2nd percentile over the trailing 10Y window (vs. 4th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 57th percentile within its industry and the 57th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.82%, ranking at the 99th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 41.6 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 3.65% comes from cash dividends, with an implied ~1.17% from buybacks — a fairly balanced mix of both channels. Shanghai Haohai Biological Technology operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.